nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Acquired ichthyosis associated with IgG4-related disease
|
Torres-Saavedra, Fabio |
|
|
|
8 |
p. e576 |
artikel |
2 |
Addressing fatigue in inflammatory rheumatic diseases
|
Thombs, Brett D |
|
|
|
8 |
p. e526-e527 |
artikel |
3 |
Adverse events after first COVID-19 vaccination in patients with autoimmune diseases
|
Boekel, Laura |
|
|
|
8 |
p. e542-e545 |
artikel |
4 |
Anifrolumab in lupus: the promise and the caution
|
Jain, Siddharth |
|
|
|
8 |
p. e461-e462 |
artikel |
5 |
Anifrolumab in lupus: the promise and the caution – Author's reply
|
Furie, Richard |
|
|
|
8 |
p. e462 |
artikel |
6 |
Antibody prevalence after three or more COVID-19 vaccine doses in individuals who are immunosuppressed in the UK: a cross-sectional study from MELODY
|
Pearce, Fiona A |
|
|
|
8 |
p. e461-e473 |
artikel |
7 |
Are treat-to-target and dose tapering strategies for rheumatoid arthritis possible during the COVID-19 pandemic?
|
Yeoh, Su-Ann |
|
|
|
8 |
p. e454-e456 |
artikel |
8 |
Calcinosis cutis universalis secondary to scleroderma-polymyositis overlap syndrome
|
Colquhoun, Matthew |
|
|
|
8 |
p. e604 |
artikel |
9 |
Canakinumab in a subgroup of patients with COVID-19
|
Ucciferri, Claudio |
|
|
|
8 |
p. e457-ee458 |
artikel |
10 |
Can tocilizumab calm the cytokine storm of COVID-19?
|
Schulert, Grant S |
|
|
|
8 |
p. e449-e451 |
artikel |
11 |
Central sensitisation: causes, therapies, and terminology
|
Cayrol, Timothée |
|
|
|
8 |
p. e548 |
artikel |
12 |
Central sensitisation: causes, therapies, and terminology
|
Minhas, Sonica |
|
|
|
8 |
p. e546 |
artikel |
13 |
Central sensitisation: causes, therapies, and terminology
|
Mehta, Puja |
|
|
|
8 |
p. e546-e547 |
artikel |
14 |
Central sensitisation: causes, therapies, and terminology
|
Weisman, Asaf |
|
|
|
8 |
p. e547-e548 |
artikel |
15 |
Central sensitisation: causes, therapies, and terminology – Authors' reply
|
Nijs, Jo |
|
|
|
8 |
p. e548-e549 |
artikel |
16 |
Clinician-reported outcome measures in lupus trials: a problem worth solving
|
Connelly, Kathryn |
|
|
|
8 |
p. e595-e603 |
artikel |
17 |
Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS): development and validation of a novel outcome measure
|
Arends, Suzanne |
|
|
|
8 |
p. e553-e562 |
artikel |
18 |
Correction to Lancet Rheumatol 2022; 4: e53–60
|
|
|
|
|
8 |
p. e530 |
artikel |
19 |
Correction to Lancet Rheumatol 2021; 3: e744–47
|
|
|
|
|
8 |
p. e530 |
artikel |
20 |
Correction to Lancet Rheumatol 2023; 5: e386–400
|
|
|
|
|
8 |
p. e440 |
artikel |
21 |
COVID-19 and systemic lupus erythematosus: a case series
|
Gartshteyn, Yevgeniya |
|
|
|
8 |
p. e452-e454 |
artikel |
22 |
CRESS: improving the assessment of disease activity in Sjögren's syndrome
|
Isenberg, David A |
|
|
|
8 |
p. e534-e535 |
artikel |
23 |
Deciphering the cytokine fingerprint of macrophage activation syndrome
|
Henderson, Lauren A |
|
|
|
8 |
p. e535-e538 |
artikel |
24 |
Definition and validation of serum biomarkers for optimal differentiation of hyperferritinaemic cytokine storm conditions in children: a retrospective cohort study
|
Kessel, Christoph |
|
|
|
8 |
p. e563-e573 |
artikel |
25 |
Development and validation of an OMERACT ultrasound scoring system for the extent of calcium pyrophosphate crystal deposition at the joint level and patient level
|
Sirotti, Silvia |
|
|
|
8 |
p. e474-e482 |
artikel |
26 |
Disease-associated and patient-specific immune cell signatures in juvenile-onset systemic lupus erythematosus: patient stratification using a machine-learning approach
|
Robinson, George A |
|
|
|
8 |
p. e485-e496 |
artikel |
27 |
EULAR 2021
|
Brooks, Helen |
|
|
|
8 |
p. e551-e552 |
artikel |
28 |
Evaluation of SARS-CoV-2 IgG antibody reactivity in patients with systemic lupus erythematosus: analysis of a multi-racial and multi-ethnic cohort
|
Saxena, Amit |
|
|
|
8 |
p. e585-e594 |
artikel |
29 |
Evaluation of the safety, efficacy, and mechanism of action of obexelimab for the treatment of patients with IgG4-related disease: an open-label, single-arm, single centre, phase 2 pilot trial
|
Perugino, Cory A |
|
|
|
8 |
p. e442-e450 |
artikel |
30 |
Exploratory analysis of the TREAT EARLIER trial: is the efficacy of temporary methotrexate treatment dose-dependent?
|
Krijbolder, Doortje I |
|
|
|
8 |
p. e437-e439 |
artikel |
31 |
Fatigue in patients with ANCA-associated vasculitis: is avacopan the answer?
|
Tervaert, Jan Willem Cohen |
|
|
|
8 |
p. e429-e430 |
artikel |
32 |
GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study
|
De Luca, Giacomo |
|
|
|
8 |
p. e465-e473 |
artikel |
33 |
GM-CSF in the treatment of COVID-19: a new conductor in the pathogenesis of cytokine storm?
|
Favalli, Ennio Giulio |
|
|
|
8 |
p. e448-e449 |
artikel |
34 |
Inflammatory biomarkers in COVID-19-associated multisystem inflammatory syndrome in children, Kawasaki disease, and macrophage activation syndrome: a cohort study
|
Rodriguez-Smith, Jackeline J |
|
|
|
8 |
p. e574-e584 |
artikel |
35 |
Lessons for rituximab therapy in patients with rheumatoid arthritis
|
Garcia-Montoya, Leticia |
|
|
|
8 |
p. e497-e509 |
artikel |
36 |
Maintaining momentum on gender equity
|
The Lancet Rheumatology, |
|
|
|
8 |
p. e427 |
artikel |
37 |
Making a big impact with small datasets using machine-learning approaches
|
Choi, May Y |
|
|
|
8 |
p. e451-e452 |
artikel |
38 |
NICE approves romosozumab for postmenopausal osteoporosis
|
Thorley, Jennifer |
|
|
|
8 |
p. e532 |
artikel |
39 |
NICE guidance for moderate RA—a step in the right direction
|
The Lancet Rheumatology, |
|
|
|
8 |
p. e533 |
artikel |
40 |
Obexelimab in IgG4-related disease: B-cell inhibition as a novel therapeutic approach
|
Alexander, Tobias |
|
|
|
8 |
p. e428-e429 |
artikel |
41 |
Opioid use in rheumatic diseases: preventing another pandemic
|
The Lancet Rheumatology, |
|
|
|
8 |
p. e447 |
artikel |
42 |
Pan American League of Associations for Rheumatology Guidelines for the treatment of ANCA-associated vasculitis
|
Magri, Sebastián Juan |
|
|
|
8 |
p. e483-e494 |
artikel |
43 |
Patient and public involvement in rheumatology research: embracing the wave of change
|
Yeoh, Su-Ann |
|
|
|
8 |
p. e540-e542 |
artikel |
44 |
Penélope Palominos: rheumatology by sight and touch
|
Burki, Talha |
|
|
|
8 |
p. e533 |
artikel |
45 |
Predicting COVID-19 vaccination response in populations who are immunosuppressed
|
Bechman, Katie |
|
|
|
8 |
p. e431-e432 |
artikel |
46 |
Pulmonary intravascular coagulopathy in COVID-19 pneumonia
|
Reines, Brandon P |
|
|
|
8 |
p. e458-e459 |
artikel |
47 |
Pulmonary intravascular coagulopathy in COVID-19 pneumonia
|
Brondani, Giovanni |
|
|
|
8 |
p. e458 |
artikel |
48 |
Pulmonary intravascular coagulopathy in COVID-19 pneumonia
|
Cárdenas Suri, Hisyovi |
|
|
|
8 |
p. e459-e460 |
artikel |
49 |
Pulmonary intravascular coagulopathy in COVID-19 pneumonia – Authors' reply
|
McGonagle, Dennis |
|
|
|
8 |
p. e460-e461 |
artikel |
50 |
Remotely delivered cognitive behavioural and personalised exercise interventions for fatigue severity and impact in inflammatory rheumatic diseases (LIFT): a multicentre, randomised, controlled, open-label, parallel-group trial
|
Bachmair, Eva-Maria |
|
|
|
8 |
p. e534-e545 |
artikel |
51 |
Research in Brief
|
Thorley, Jennifer |
|
|
|
8 |
p. e531 |
artikel |
52 |
Research in Brief
|
Thorley, Jennifer |
|
|
|
8 |
p. e550 |
artikel |
53 |
Research in Brief
|
Thorley, Jennifer |
|
|
|
8 |
p. e463 |
artikel |
54 |
Research in Brief
|
Thorley, Jennifer |
|
|
|
8 |
p. e441 |
artikel |
55 |
Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial
|
Ebata, Satoshi |
|
|
|
8 |
p. e546-e555 |
artikel |
56 |
Seza Ozen
|
Burki, Talha Khan |
|
|
|
8 |
p. e464 |
artikel |
57 |
Shared genetic susceptibility between trigger finger and carpal tunnel syndrome: a genome-wide association study
|
Patel, Benjamin |
|
|
|
8 |
p. e556-e565 |
artikel |
58 |
Systemic lupus erythematosus does not prevent antibody responses to SARS-CoV-2
|
Aringer, Martin |
|
|
|
8 |
p. e538-e540 |
artikel |
59 |
Systemic sclerosis in the time of COVID-19
|
Hoffmann-Vold, Anna-Maria |
|
|
|
8 |
p. e566-e575 |
artikel |
60 |
Takayasu arteritis with pyoderma gangrenosum and superficial thrombophlebitis
|
Acharya, Nupoor |
|
|
|
8 |
p. e510 |
artikel |
61 |
The demise of Roe v Wade: ramifications for rheumatology
|
The Lancet Rheumatology, |
|
|
|
8 |
p. e525 |
artikel |
62 |
The impact of COVID-19 on rheumatology health-care workers and their scientific output: heavy lies the crown on women in rheumatology
|
Andrews, Margaret R |
|
|
|
8 |
p. e434-e436 |
artikel |
63 |
The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial
|
Strand, Vibeke |
|
|
|
8 |
p. e451-e460 |
artikel |
64 |
Tocilizumab in patients with severe COVID-19: a retrospective cohort study
|
Guaraldi, Giovanni |
|
|
|
8 |
p. e474-e484 |
artikel |
65 |
Ultrasound: a tool to quantify calcium pyrophosphate deposits
|
Latourte, Augustin |
|
|
|
8 |
p. e432-433 |
artikel |
66 |
When the game changes: efficacy of rituximab in systemic sclerosis
|
Ong, Voon H |
|
|
|
8 |
p. e527-e529 |
artikel |